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Lung cancer is the leading cause of cancer-related death 
and continues to be a major global health problem (1). 
Nevertheless, as a result of advances in imaging techniques 
and the introduction of screening programs, significant 
progress in early stage diagnosis and reduction in mortality 
is observed (2). The increasing detection numbers of early 
staged non-small cell lung cancer (NSCLC) elicit multiple 
questions concerning the appropriate treatment approach in 
these patients. 
Lobectomy with R0 resection and lymph node dissection 
is considered a standard surgical procedure for patients 
with NSCLC (3,4). However, according to multiple studies, 
sub-lobar resections, particularly segmentectomy, seem 
to provide equivalent survival rates for small peripheral 
lung cancer (5-7), especially for patients with limited life 
expectancy (7-9). Still, limited resection is associated with 
an increased risk of positive surgical margins and inadequate 
lymphadenectomy (10), which should be taken into 
consideration. The question whether the limited resection 
might be considered oncologically equivalent to lobectomy 
in early-stage NSCLC still remains unanswered.
Furthermore, some authors suggested that systematic 
lymph node dissection could be limited or even avoided in 
case of small peripheral lung cancer. However, the lymph 
node involvement, including N1 and N2 stages, in sub-
centimetre tumours has been reported in a range of 0–15% 
(11-13). As a result, the lymph node dissection still remains 
the standard approach. Nonetheless, the search for reliable 
N0 stage predictive factors continues (13,14).
The fourth edition of the WHO classification of 
Tumours of the Lung, Pleura and Thymus introduced the 
new classification for lung adenocarcinoma, as proposed by 
the International Association for the Study of Lung Cancer/
American Thoracic Society/European Respiratory Society 
(IASLC/ATS/ERS). The histological subtyping has been 
proven to be of prognostic significance and the introduced 
subtypes: adenocarcinoma in situ (AIS) and minimally 
invasive adenocarcinoma (MIA) are associated with a near 
100% disease-specific survival after complete resection 
(15,16). Therefore, histological subtyping might be useful 
to determine the type of surgical management in stage I 
lung adenocarcinoma. However, the correct recognition of 
the predominant histological subtype in preoperative biopsy 
or intraoperative frozen section remains a challenge (17). 
In the article ‘Clinical characteristics and advantages of 
primary peripheral micro-sized lung adenocarcinoma over 
small-sized lung adenocarcinoma’ by Zhu et al., the authors 
retrospectively analysed data of 366 patients with primary 
peripheral lung adenocarcinoma and tumour size <2 cm in 
maximum diameter, treated in the period from 2007 to 2013. 
The objective of the study was to estimate the overall survival 
and lung cancer-specific survival in these patients (18).
The authors propose a new term ‘micro-sized lung 
adenocarcinoma’ defined as a tumour of 1.0 cm or less in 
maximum diameter, which seems unnecessary considering 
that these tumours have recently been defined as T1a in the 
eighth edition of the TNM Classification for Lung Cancer. 
According to Rami-Porta et al., a progressive degradation of 
survival is observed for each 1-cm cut-point in tumour size 
and therefore a subclassification of present pT1 category 
into T1a (≤1 cm), T1b (>1 and ≤2 cm) and T1c (>2 and 
≤3 cm) based on tumour size was proposed (19). Taking 
these results into consideration, the study by Zhu et al. 
confirmed that lung adenocarcinoma patients with a tumour 
of 1.0 cm or less in diameter had better 5-year overall and 
disease-specific survival rates than patients with a tumour of 
1.1–2.0 cm (100% vs. 88.4% and 100% vs. 89%, P<0.001, 
respectively). 
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Noticeably, the authors observed no significant difference 
in the overall and lung adenocarcinoma-specific survival 
rates with regard to the surgical procedure undergone. 
However, even though the 5-year overall and disease-
related survival rates of 92.2% and 94.0% for patients who 
had lobectomy and 95.9% and 81.0% for patients who 
had limited resection (P=0.349, 0.124, respectively) are 
statistically insignificant, these differences should be taken 
into consideration. Moreover, no significant differences 
between the tumour size and surgical procedure with 
regard to 5-year survival rates were observed. Perhaps 
it would have been interesting to include in the analysis 
the information about the limited resection type, i.e., to 
examine the postoperative survival after lobectomy vs. 
segmentectomy vs. wedge resection in patients with T1a 
and T1b tumours. 
In the study, the patients routinely received chest CT 
scans and mediastinoscopy before surgical treatment. 
According to the Revised ESTS guidelines for preoperative 
mediastinal lymph node staging for NSCLC by De Leyn 
et al., the mediastinal nodal staging in patients with 
suspected or proven NSCLC should include positron 
emission tomography (PET) and endosonography: 
endobronchia l  u l trasound with real-t ime guided 
transbronchial needle aspiration (EBUS-TBNA) and 
esophageal ultrasound with fine needle aspiration (EUS-
FNA), which is recommended over surgical staging as the 
initial procedure. Moreover, in patients with suspected or 
proven <3 cm peripheral NSCLC with normal mediastinal 
and hilar nodes at CT and/or PET, direct surgical 
resection with systematic nodal dissection, without further 
preoperative mediastinal staging is advised (20). These 
recommendations seem applicable for patients included in 
the study by Zhu et al.
The authors suggested that lung adenocarcinoma 
tumours smaller than 1.0 cm in diameter and a subtype 
of AIS evaluated by CT images or intraoperative frozen 
section may be appropriate candidates for limited resection 
without mediastinal lymph node dissection. In the study the 
lymphatic metastasis rates for patients with a tumour size of 
1.0 cm or less and 1.1–2.0 cm were 0 and 9%, respectively. 
However, the patients only underwent mediastinal sampling 
and systematic lymph node dissection was not performed. 
Therefore the results regarding the N stage may not be 
reliable and the proposal of omitting mediastinal lymph 
node dissection seems not justified—this important issue 
warrants further studies.
Additionally, the authors admitted that lack of the 
recurrence data for the disease is a limitation of the study. 
Indeed, it would be of great interest to know the pattern 
of recurrence (local, mediastinal, distal) with respect to the 
size of the tumour and type of resection (segmentectomy, 
wedge), in order to determine the type of resection allowing 
to minimize the risk of recurrence. 
In conclusion, the article ‘Clinical characteristics 
and advantages of primary peripheral micro-sized lung 
adenocarcinoma over small-sized lung adenocarcinoma’ 
by Zhu et al. confirms the findings of previous publications 
and re-opens the debate on the reassessment of the 
optimal treatment approach for small-sized lung cancer. 
Will the limited resection replace the today’s golden 
standard of early-stage NSCLC treatment: lobectomy with 
systematic lymph node dissection? The debate is open, the 
controversies remain. Many questions still need answering 
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